PBC Clinical Trial - Response Study
Share this page

Latest News

All the latest PBC Foundation news; events, announcements, surveys, and more.

PBC Clinical Trial - Response Study

PBC Clinical Trial - Response Study

The RESPONSE study is seeking people living with primary biliary cholangitis (PBC) for a Phase 3 clinical research study being conducted to learn more about the effectiveness and safety of a new investigational drug, seladelpar.

The RESPONSE study is enrolling patients who have been using ursodeoxycholic acid (UDCA or ursodiol) but have not achieved the recommended treatment goal or who developed troublesome side effects from UDCA that prevent them from continuing to take this treatment. The study will evaluate if seladelpar can improve PBC-related blood laboratory tests and can improve symptoms of PBC, such as itching. 

For more information and your opportunity to participate, click here.